Cargando…

Can Aliskiren be Considered as a New Novel Drug for Hypertension?

Hypertension is one of the most common causes of death across the globe. Many trials and drugs have been used for controlling the debilitating effects of hypertension. One such new class of drug is direct renin inhibitors (DRI), e.g., aliskiren, which block the renin-angiotensin system (RAS). It blo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatti, Adnan Bashir, Gazali, Zarine Anwar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671838/
https://www.ncbi.nlm.nih.gov/pubmed/26677425
http://dx.doi.org/10.7759/cureus.375
_version_ 1782404461364248576
author Bhatti, Adnan Bashir
Gazali, Zarine Anwar
author_facet Bhatti, Adnan Bashir
Gazali, Zarine Anwar
author_sort Bhatti, Adnan Bashir
collection PubMed
description Hypertension is one of the most common causes of death across the globe. Many trials and drugs have been used for controlling the debilitating effects of hypertension. One such new class of drug is direct renin inhibitors (DRI), e.g., aliskiren, which block the renin-angiotensin system (RAS). It blocks the very first step in the RAS system. Multiple trials have been carried out debating the outcome of monotherapy and combination therapy with other classes of hypertensive drugs. Focus on compliance, adverse effects, and the cost have also been in the news. Extensive studies are still needed to justify the clinical use of a DRI in the effective treatment of hypertension.
format Online
Article
Text
id pubmed-4671838
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-46718382015-12-16 Can Aliskiren be Considered as a New Novel Drug for Hypertension? Bhatti, Adnan Bashir Gazali, Zarine Anwar Cureus Internal Medicine Hypertension is one of the most common causes of death across the globe. Many trials and drugs have been used for controlling the debilitating effects of hypertension. One such new class of drug is direct renin inhibitors (DRI), e.g., aliskiren, which block the renin-angiotensin system (RAS). It blocks the very first step in the RAS system. Multiple trials have been carried out debating the outcome of monotherapy and combination therapy with other classes of hypertensive drugs. Focus on compliance, adverse effects, and the cost have also been in the news. Extensive studies are still needed to justify the clinical use of a DRI in the effective treatment of hypertension. Cureus 2015-11-04 /pmc/articles/PMC4671838/ /pubmed/26677425 http://dx.doi.org/10.7759/cureus.375 Text en Copyright © 2015, Bhatti et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Bhatti, Adnan Bashir
Gazali, Zarine Anwar
Can Aliskiren be Considered as a New Novel Drug for Hypertension?
title Can Aliskiren be Considered as a New Novel Drug for Hypertension?
title_full Can Aliskiren be Considered as a New Novel Drug for Hypertension?
title_fullStr Can Aliskiren be Considered as a New Novel Drug for Hypertension?
title_full_unstemmed Can Aliskiren be Considered as a New Novel Drug for Hypertension?
title_short Can Aliskiren be Considered as a New Novel Drug for Hypertension?
title_sort can aliskiren be considered as a new novel drug for hypertension?
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671838/
https://www.ncbi.nlm.nih.gov/pubmed/26677425
http://dx.doi.org/10.7759/cureus.375
work_keys_str_mv AT bhattiadnanbashir canaliskirenbeconsideredasanewnoveldrugforhypertension
AT gazalizarineanwar canaliskirenbeconsideredasanewnoveldrugforhypertension